List view / Grid view
9 May 2016 | By L.B. Bohle Maschinen + Verfahren GmbH
The company’s history began with a blender in 1987 – in the meantime, L.B. Bohle, the machine builder from Ennigerloh, has manufactured more than 3,000 blenders...
9 May 2016 | By Victoria White, Digital Content Producer
The companies will also enter into a license agreement whereby Incyte will obtain an exclusive license to develop and commercialise Iclusig...
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
9 May 2016 | By Victoria White, Digital Content Producer
MGB Biopharma presented Phase I and preclinical data together with a proposal for the further development of oral MGB-BP-3 in C. difficile infections...
Researchers are developing a new kind of treatment, an antibody-based drug called 3BNC117, that may provide a better strategy for long-term control of HIV...
9 May 2016 | By Victoria White, Digital Content Producer
Allergan and Richter have announced positive results from Venus I, evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids...
6 May 2016 | By Victoria White, Digital Content Producer
Akili has started enrolment for its pivotal STARS-ADHD trial that will evaluate the safety and efficacy of the company’s proprietary platform, Project: EVO...
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy.
6 May 2016 | By Victoria White, Digital Content Producer
Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia...
5 May 2016 | By Victoria White, Digital Content Producer
Eribulin is approved for those patients who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease...
5 May 2016 | By Victoria White, Digital Content Producer
Ergomed is acquiring 100% of the issued share capital of Haemostatix for an initial consideration of £8.0 million...
4 May 2016 | By Quotient Clinical
Quotient Clinical and Upperton have announced a partnership to address drug delivery challenges...
The Swiss-German biotech company, VAXIMM AG, has announced the enrolment of its first patient in a Phase 2a clinical trial for immunotherapy, VXM01.
4 May 2016 | By Victoria White, Digital Content Producer
NICE has allowed extra time for further discussions on access arrangements for PTC Therapeutics’ Translarna (ataluren) for Duchenne Muscular Dystrophy...
4 May 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.
